
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson is taking proactive steps to improve its financials through share repurchases and debt paydown, and its prospects for growth are solid with positive results in its first quarter and a focus on efficiency. While there are risks and potential challenges, BD remains committed to its growth and shareholder returns through its capital allocation plan. On a financial level, BD has a strong pipeline for acquisitions and is well-positioned in high-growth markets, with international revenue accounting for 43% of its business.
Bears say
Becton Dickinson is a global leader in the medical technology industry, with a diverse portfolio of products aimed at improving healthcare delivery. However, their recent spinoff of their Biosciences and Diagnostic Solutions business combined with ongoing headwinds may impact their growth trajectory. Additionally, competition and changes in healthcare delivery could pose risks to their business.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares